IECSCYL, Spain.
Cancer Biomark. 2010;6(5-6):247-56. doi: 10.3233/CBM-2009-0139.
Breast cancer is the second leading cause of cancer death in women in the United States. While mammography and breast magnetic resonance imaging (MRI) improve detection of early disease, there remains an unmet need for biomarkers for risk stratification, early detection, prediction, and disease prognosis. Sera from patients with breast cancer contain specific autoantibodies (AAb) to tumor antigens that develop as part of the natural immune response to cancer-associated changes in protein structure and expression. The recent development of proteomic tools for AAb detection, including protein microarrays, reverse-phase protein immunoblots, and phage display have identified a number of potential AAb biomarkers for clinical development. Immune response signatures have been identified that are highly specific, but with variable sensitivities for cancer detection. This review focuses on the detection and application of AAb signatures as biomarkers for breast cancer detection and monitoring.
乳腺癌是美国女性癌症死亡的第二大主要原因。虽然乳房 X 光摄影和乳房磁共振成像（MRI）提高了早期疾病的检出率，但仍需要生物标志物来进行风险分层、早期检测、预测和疾病预后。患有乳腺癌的患者的血清中含有针对肿瘤抗原的特异性自身抗体（AAb），这些自身抗体是作为对与癌症相关的蛋白质结构和表达变化的自然免疫反应的一部分而产生的。最近开发的用于 AAb 检测的蛋白质组学工具，包括蛋白质微阵列、反相蛋白免疫印迹和噬菌体展示，已经确定了许多用于临床开发的潜在 AAb 生物标志物。已经确定了免疫反应特征，这些特征对癌症检测具有高度特异性，但敏感性不同。本文综述了 AAb 标志物作为乳腺癌检测和监测的生物标志物的检测和应用。
